VivoSeq
Other

Colitis, Ulcerative

20

Pipeline Programs↗

15

Active Trials↗

5

Companies Involved↗

Colitis, Ulcerative is an emerging landscape with 20 programs across 5 companies. The most active players are Sanofi, Pfizer, Merck & Co.. 10 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

27/100

Mech. Concentration

40/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

2 programs

Phase 2Pfizer logo

Pfizer

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 2Johnson & Johnson logo

Johnson & Johnson

9 programs

Phase 3Eli Lilly logo

Eli Lilly

4 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

64%

Small molecule

7 of 11 classified programs — the dominant modality here.

36%ALL OTHERSMonoclonal antibody436%

Small molecule leads; the ring shows all 11 classified programs, each share of the total. Modality classified for 57% of 21 pipeline programs.

Analysis

Trial Status

15

clinical trials

Recruiting10 · 67%
Active, not recruiting5 · 33%

Clinical Trials

Trial Activity

15 trials

A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Adult Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting·Merck & Co. logoMerck & Co.·Phase 2·NCT07463183·100 enrolled
A Multi-Center, Prospective, Non-Interventional Study of Real-World Effectiveness of Etrasimod in Patients With Ulcerative Colitis (ENDEAVOUR-UC)
Recruiting·Pfizer logoPfizer·N/A·NCT06398626·300 enrolled
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Confirm Efficacy and Safety of MH002 and to Assess the Effect of Dose in Patients With Mild-to- Moderate Ulcerative Colitis Insufficiently Controlled With 5-Aminosalicylic Acid
Recruiting·MMRM Health NV·Phase 2·NCT07296315·204 enrolled
A Master Protocol for Phase 2, Randomized, Controlled Studies of Multiple Interventions for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
Recruiting·Eli Lilly logoEli Lilly·Phase 2·NCT07483073·60 enrolled
A Phase 3 Randomized, Double-blind, and Active Controlled, Multi-center Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT07577856·644 enrolled
Guselkumab Real-world Effectiveness Among Bio-NaÏve Patients With Moderate-to-severe Ulcerative Colitis in China: A Multicenter, Non-interventional, Prospective Study
Recruiting·Johnson & Johnson logoJohnson & Johnson·N/A·NCT07302360·200 enrolled
A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults With an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy With Icotrokinra in Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT07196748·882 enrolled
A PHASE 2 OPEN-LABEL, SINGLE ARM STUDY TO EVALUATE THE EFFICACY, PHARMACOKINETICS, AND SAFETY OF ETRASIMOD IN PEDIATRIC PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Recruiting·Pfizer logoPfizer·Phase 2·NCT07470879·24 enrolled
A Phase 2, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR441566 in Adults With Moderate-to-severe Ulcerative Colitis
Recruiting·Sanofi logoSanofi·Phase 2·NCT06867094·204 enrolled
Effectiveness of Etrasimod on Disease Activity and Patient-reported Outcomes in Ulcerative Colitis - EFFECT-UC
Recruiting·Pfizer logoPfizer·N/A·NCT06294925·360 enrolled
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT05528510·418 enrolled
A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 2·NCT05242484·577 enrolled
A Phase 3 Randomized, Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Golimumab Treatment, a Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT03596645·84 enrolled
A Phase 3 Randomized, Open-label Induction, Double-blind Maintenance, Parallel-group, Multicenter Protocol to Evaluate the Efficacy, Safety, and Pharmacokinetics of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT06260163·112 enrolled
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype
Active, not recruiting·Sanofi logoSanofi·Phase 2·NCT05731128·68 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)